Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 study of XC001 as adjunctive therapy in patients with coronary artery bypass grafting (CABG)

Next Previous
Trial Profile

A Phase 2 study of XC001 as adjunctive therapy in patients with coronary artery bypass grafting (CABG)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 07 Jan 2025 According to XyloCor Therapeutics media release, company aims to initiate a second Phase 2 trial of XC001 in 2025 as an adjunctive therapy to augment the effectiveness of CABG
  • 10 Jul 2024 According to XyloCor Therapeutics media release, the company have entered into a licensing agreement under which XyloCor has rights to the Extroducer Infusion Catheter System , a first-in-class endovascular device designed to deliver advanced therapies directly into the heart; XyloCor plans to deploy the Extroducer to support catheter-based endocardial delivery of XC001
  • 29 Jul 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top